About ReNeuron
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead therapeutic candidate is our ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. Patient recruitment for a ground-breaking first-in-man trial of ReN001 has recently commenced in the UK. Our ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. We are also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.
We have also developed a range of stem cell lines for non-therapeutic applications - our ReNcell® products for use in academic and commercial research. Our ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.
Our shares are traded on the London AIM market under the symbol RENE.L.
Top of page